We have won a number of multi-country remits across the Group including coordinating and working on an eleven country programme for the navigation systems company MyGuide and a campaign for Land Rover's sustainability programme across twelve markets.
In the UK, Huntsworth Health showed strong growth and margins and we continue to focus on maintaining excellent margins in our newly acquired companies in the USA. While Huntsworth Health's business covers a breadth of disciplines, the two areas showing greatest momentum are digital and medical communications.
Our domestic franchises in the UK and in the US still generate the greatest revenues. However we are seeing a significant strengthening of our global and pan-European business.
Domestic new clients for Huntsworth Health include Animas, Baxter BioSurgery, Shire, Merck-Serono and Hospira with new projects from existing clients including Celgene, Idev Technologies, AstraZeneca, Abbott Laboratories, Allergan and Pfizer. The majority of wins have been for brands in specialist therapeutic areas including diabetes, breast cancer, anti-infectives and hypertension.
New European clients for Huntsworth Health include Daiichi-Sankyo, Pfizer and Novartis Vaccines, and global accounts won include Roche, Novartis, Intercell and Iroko. Our multi-disciplinary business is also increasing, and whilst most clients still offer new projects and pitches in one area (advertising or public relations, for example), we are regularly broadening our franchise with both domestic and European clients to offer a range of services on specific brands.
Peter Chadlington, Huntsworth CEO, said, "The year has begun
|SOURCE Huntsworth plc|
Copyright©2008 PR Newswire.
All rights reserved